Revised: October 2013
The recommended influenza vaccine composition for New Zealand in 2014 is:
* A/Texas/50/2012 is an A(H3N2) virus that, following adaptation to growth in eggs, has maintained antigenic properties similar to the majority of recently circulating cell-propagated A(H3N2) viruses including A/Victoria/361/2011.
For applicants intending to submit a NMA for a quadrivalent influenza vaccine, the recommended composition for New Zealand in 2014 is as listed above, plus the additional B virus:
Vaccine strains recommended as suitable are those listed on the World Health Organisation (WHO) Influenza vaccine viruses and reagents web pages (see http://www.who.int/influenza/vaccines/virus/candidates_reagents/home/en/index.html) for H1N1, H3N2 and B viruses.
This recommendation is based on the outcome of: